AbolerIS Pharma is developing a first-in-class monoclonal antibody that induces immune tolerance to treat chronic autoimmune and inflammatory diseases, including transplant rejection and graft-versus-host disease. Their approach aims to restore immune system balance while preserving beneficial immune responses, addressing the challenges of managing these complex conditions.

AnaCardio is developing novel inotropic agents that enhance cardiomyocyte contractility through the ghrelin signaling pathway, aiming to improve cardiac output without increasing oxygen consumption or mortality. This approach addresses the unmet need for effective treatments that target impaired contractility in heart failure patients, potentially improving organ function and quality of life.

AntagomiR develops anti-miR oligonucleotides targeting upregulated microRNAs in myotonic dystrophy patients, addressing the underlying toxic DMPK and insufficient MBNL levels. Their fatty acid-conjugated delivery system enables effective treatment with a significantly reduced active dose directly to muscle tissue.

The startup develops a stem cell therapy utilizing novel mesenchymal stem cells with enhanced osteogenic potential for the treatment of osteogenesis imperfecta. This therapy enables targeted bone formation by allowing the stem cells to migrate and engraft in the patient's bone, facilitating early intervention and improving long-term patient outcomes.

The startup develops orally administered small molecules for the treatment of retinal vascular diseases, specifically targeting diabetic retinopathy and age-related macular degeneration. By focusing on de-risked and scientifically validated therapies, the company aims to provide safer and more accessible treatment options for patients suffering from these conditions.

Ro operates a telehealth platform that provides online clinics for weight loss, sexual health, hair restoration, and fertility management using clinically proven treatments and prescription medications. The service eliminates the need for insurance and offers free, discreet shipping, making healthcare accessible and convenient for over 2 million members.

Teitur Trophics develops cyclic peptides targeting Sortilins receptors to create therapeutics for neurodegenerative diseases such as Huntington’s, Parkinson’s, and Frontotemporal Dementia. The company addresses the lack of effective treatments for over 200 million patients worldwide suffering from progressive neurodegeneration that impacts memory, movement, and quality of life.

The startup operates a phenotypic screening platform that utilizes oncolytic viruses to develop targeted cancer therapies for intravenous delivery. This approach enables the identification of effective treatment candidates tailored to specific patient populations, enhancing the efficacy of cancer care.

VarmX B.V. manufactures therapeutic proteins that rapidly restore hemostasis in patients experiencing acute bleeding. This technology provides a critical solution for medical emergencies by enabling immediate blood clotting, thereby reducing the risk of severe complications.